Polyrizon Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025

Polyrizon (Nasdaq: PLRZ) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on March 25, 2026.

Rhea-AI Summary

Polyrizon (Nasdaq: PLRZ) filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission on March 25, 2026.

The report is available on the SEC website and Polyrizon’s investor relations site; shareholders may request a free copy from Investor Relations at IR@polyrizon-biotech.com.

Argus Mar 26 session

-3.37% close to close Open Argus

Details

News Market Reaction – PLRZ

On Mar 26, the first trading day after this news, PLRZ closed 3.37% below the previous close.

Data tracked by StockTitan Argus for the Mar 26 session.

Key Figures

Operating loss 2025: $6.249 million Operating loss 2024: $1.302 million Accumulated deficit: $8.4 million +5 more

Operating loss 2025

$6.249 million

Year ended December 31, 2025 (Form 20-F)

Operating loss 2024

$1.302 million

Year ended December 31, 2024 (Form 20-F)

Accumulated deficit

$8.4 million

As of December 31, 2025 (Form 20-F)

Ordinary shares outstanding

1,608,266 shares

As of December 31, 2025 (Form 20-F)

Cash & cash equivalents

$1.3 million

As of December 31, 2025 (Form 20-F)

Bank deposits

$16.2 million

As of December 31, 2025 (Form 20-F)

Shelf capacity

$50,000,000

Form F-3 shelf registration

Short interest

3.58%

Current reported short interest percent

Historical Context

5 past events · Latest: Mar 24

5 events

1. Mar 24

   Acquisition MOU

   24h Move

   -5.0%

   Non-binding MOU to acquire up to 20% of Colugo for up to $6M.

2. Mar 17

   Clinical trial prep

   24h Move

   -4.2%

   Agreement with global preclinical CRO for GLP biocompatibility studies.

3. Mar 10

   GMP manufacturing

   24h Move

   -0.1%

   Successful GMP batch of CTM supporting planned U.S. clinical study.

4. Feb 26

   Preclinical data

   24h Move

   +1.1%

   Naloxone formulation showed improved nasal deposition vs. reference product.

5. Feb 17

   Product branding

   24h Move

   +0.4%

   Unveiling NASARIX™ brand and outlining planned clinical timeline.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 20-f, u.s. securities and exchange commission, nasdaq, pre-clinical-stage, +1 more

5 terms

form 20-f regulatory

"filed its Annual Report on Form 20-F for the fiscal year ended"

Form 20-F is the standardized annual disclosure that non-U.S. companies must file with the U.S. securities regulator when their shares are traded in the U.S.; it contains audited financial statements, a plain-language description of the business, management discussion, governance details and key risk factors. It matters to investors because it provides a consistent, comparable company “report card” and rulebook, helping buyers assess financial health, governance and risks before investing.

u.s. securities and exchange commission regulatory

"for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission"

The U.S. Securities and Exchange Commission is a government agency responsible for overseeing the stock market and protecting investors. It sets rules to ensure that companies share truthful information and that trading is fair, helping to maintain trust in the financial system. This oversight is important because it helps prevent fraud and ensures that investors can make informed decisions.

nasdaq financial

"Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

View in glossary

pre-clinical-stage medical

"the “Company”), a pre-clinical-stage biotechnology company developing intranasal"

Pre-clinical-stage describes the phase of developing a medical product or therapy that happens before any testing in humans, when researchers use laboratory experiments and animal studies to evaluate safety, biological activity, and dosing. Investors care because this is an early, high-risk point where results can make or break a program — like testing a car prototype in the workshop before any road trials — and positive data can significantly raise value while failures can wipe it out.

intranasal medical

"biotechnology company developing intranasal protective solutions, today announced"

Administration or delivery of a drug or vaccine through the nose, typically via a spray or drops that are absorbed by the nasal tissues. For investors, intranasal products can matter because they often offer easier, needle-free use, faster onset of effect, and potential cost or compliance advantages that can widen a product’s market and affect regulatory review, manufacturing complexity, and commercial prospects — similar to how a convenient app can outsell a clunky desktop program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC").

The report is available on the SEC's website, at www.sec.gov and Polyrizon’s Investor Relations website, at https://investor.polyrizon-biotech.com/.

Shareholders can obtain copies of Polyrizon’s Annual Report on Form 20-F, free of charge, by making a request within a reasonable period of time to Polyrizon’s Investor Relations Department at IR@polyrizon-biotech.com.

About Polyrizon

Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays, which form a thin hydrogel-based shield containment barrier in the nasal cavity that can provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity. Polyrizon are further developing certain aspects of our C&C hydrogel technology such as the bioadhesion and prolonged retention at the nasal deposition site for intranasal delivery of drugs. Polyrizon refers to its additional technology, which is in an earlier stage of pre-clinical development, that is focused on nasal delivery of active pharmaceutical ingredients, or APIs, as Trap and Target ™, or T&T. For more information, please visit https://polyrizon-biotech.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on March 24, 2026 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Polyrizon is not responsible for the contents of third-party websites.

Contacts:

Michal Efraty
Investor Relations
IR@polyrizon-biotech.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Polyrizon (PLRZ) file on March 25, 2026?

Polyrizon filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025. According to the company, the filing is available on the SEC website and on Polyrizon’s investor relations site for shareholder review.

Where can investors access Polyrizon's (PLRZ) 20-F for 2025?

Investors can access the 20-F on the SEC website and Polyrizon’s investor relations website. According to the company, the report is posted at www.sec.gov and at https://investor.polyrizon-biotech.com for download or review.

How can shareholders obtain a free copy of Polyrizon's (PLRZ) 2025 Annual Report?

Shareholders can request a free copy by contacting Polyrizon’s Investor Relations at IR@polyrizon-biotech.com. According to the company, requests should be made within a reasonable period to receive the Annual Report free of charge.

What period does Polyrizon's (PLRZ) filed 20-F cover?

The filed Form 20-F covers the fiscal year ended December 31, 2025. According to the company, that reporting period is the basis for the annual disclosure in the March 25, 2026 filing.

Does the Polyrizon (PLRZ) filing include clinical or financial tables investors should review?

The company’s 20-F filing contains structured tables and clinical-stage disclosures for review. According to the company, investors should consult the posted report on the SEC or investor relations site for full details.